Environmental attributes of pharmaceutical active ingredients and / or intermediates

Abstract

Disclosed are a system for producing a pharmaceutical active ingredient and / or intermediate associated with a digital asset, a method for producing a pharmaceutical active ingredient and / or intermediate associated with a digital asset, an apparatus for generating a digital asset, a computer implementation method for generating a chemical passport, a computer program element for generating a digital asset, the use of a pharmaceutical active ingredient and / or intermediate associated with a digital asset, the use of a digital asset, a product produced from a pharmaceutical active ingredient and / or intermediate and associated with a digital asset, a digital asset including one or more distributed identifiers and data relating to environmental impact data, an apparatus for producing a product associated with a digital asset, and a method for producing a product associated with a digital asset.

Description

Technical Field

[0001] The present disclosure relates to a system for generating a pharmaceutical active ingredient and / or an intermediate thereof associated with a pharmaceutical active ingredient and / or an intermediate passport or digital asset, a method for generating a pharmaceutical active ingredient and / or an intermediate thereof associated with a pharmaceutical active ingredient and / or an intermediate passport or digital asset, an apparatus for generating a passport or digital asset associated with a pharmaceutical active ingredient and / or an intermediate thereof, a computer-implemented method for generating a pharmaceutical active ingredient and / or an intermediate passport or digital asset, a computer program element for generating a pharmaceutical active ingredient and / or an intermediate passport or digital asset, the use of a pharmaceutical active ingredient and / or an intermediate thereof associated with a pharmaceutical active ingredient and / or an intermediate passport or digital asset, the use of a pharmaceutical active ingredient and / or an intermediate passport or digital asset, a product produced from a pharmaceutical active ingredient and / or an intermediate thereof and associated with a pharmaceutical active ingredient and / or an intermediate passport or digital asset, a pharmaceutical active ingredient and / or an intermediate passport or digital asset comprising one or more dispersion identifiers of a pharmaceutical active ingredient and / or an intermediate thereof and data related to environmental impact data, an apparatus for producing a product associated with a pharmaceutical active ingredient and / or an intermediate passport or digital asset, and a method for producing a product associated with a pharmaceutical active ingredient and / or an intermediate passport or digital asset.

Background Art

[0002] In the supply chain, the environmental impact of each supply chain participant is a major concern. Particularly in the field of chemistry, pharmaceutical active ingredients and / or their intermediates are employed in a wide range of applications and supplied to various value chains.

Summary of the Invention

Problems to be Solved by the Invention

[0003] In such complex systems, achieving transparency among value chain stakeholders is difficult. [Means for solving the problem]

[0004] In one embodiment, a system for producing a pharmaceutical active ingredient and / or its intermediate associated with a pharmaceutical active ingredient and / or its intermediate passport and digital assets is disclosed, and the system is - A chemical production network configured to produce pharmaceutical active ingredients and / or intermediates thereof, wherein the pharmaceutical active ingredients and / or intermediates thereof are produced from one or more input materials through one or more chemical processes of the chemical production network, and the one or more input materials and / or one or more chemical processes are associated with environmental attributes, - A production operating device, The system provides a dispersed identifier associated with the produced pharmaceutical active ingredient and / or its intermediates, and one or more environmental attributes of one or more input materials and / or one or more chemical processes. A production operating device configured to generate a pharmaceutical active ingredient and / or intermediate passport or digital asset by linking distributed identifiers and environmental attributes, - Optionally, the chemical production network or system is configured to provide the produced active pharmaceutical ingredients and / or intermediates in association with an active pharmaceutical ingredient and / or intermediate passport or digital asset.

[0005] In another embodiment, a system for producing pharmacovigilant active ingredients and / or intermediates associated with a pharmacovigilant active ingredient and / or intermediate passport and digital assets is disclosed, and the system is - A chemical production network configured to produce pharmaceutical active ingredients and / or intermediates thereof from one or more input materials via a chemical process, wherein one or more input materials and / or chemical processes are associated with environmental attributes, - A production operating device configured to generate a pharmaceutical active ingredient and / or intermediate passport or digital asset by providing and / or linking a distributed identifier associated with the pharmaceutical active ingredient and / or intermediate thereof with one or more environmental attributes associated with one or more input materials and / or chemical processes.

[0006] In another embodiment, a method for producing a pharmaceutical active ingredient and / or intermediate associated with a passport and digital assets is disclosed, the method is - Producing pharmaceutical active ingredients and / or intermediates from one or more input materials through one or more chemical processes in a chemical production network, wherein one or more input materials and / or one or more chemical processes are associated with environmental attributes, - Pharmaceutical active ingredients and / or intermediates passports or digital assets, To provide a dispersed identifier associated with the produced pharmaceutical active ingredient and / or its intermediates, and one or more environmental attributes associated with one or more input materials and / or one or more chemical processes, Linking a distributed identifier with one or more environmental attributes, and generating by doing so, - Including providing the produced active pharmaceutical ingredients and / or intermediates in association with an active pharmaceutical ingredient and / or intermediate passport or digital asset.

[0007] In another embodiment, a method for producing a pharmaceutical active ingredient and / or intermediate associated with a passport and digital assets is disclosed, the method is - Producing pharmaceutical active ingredients and / or intermediates from one or more input materials through one or more chemical processes in a chemical production network, wherein one or more input materials and / or one or more chemical processes are associated with environmental attributes, - This includes generating a pharmaceutical active ingredient and / or intermediate passport or digital asset by providing and / or linking a distributed identifier associated with a pharmaceutical active ingredient and / or its intermediate with one or more environmental attributes associated with one or more input materials and / or chemical processes.

[0008] In another embodiment, an apparatus for generating a passport or digital asset associated with a pharmaceutical active ingredient and / or its intermediates is disclosed, wherein the pharmaceutical active ingredient and / or its intermediates are produced from one or more input materials through one or more chemical processes of a chemical production network, the one or more input materials and / or one or more chemical processes are associated with environmental attributes, and the apparatus is - A distributed identity provider configured to provide a distributed identifier associated with the produced pharmaceutical active ingredient and / or intermediate thereof, and one or more environmental attributes of one or more input materials and / or one or more chemical processes used to produce the pharmaceutical active ingredient and / or intermediate thereof, - An assigner that has configured a distributed identifier and environmental attributes, - A passport provider configured to provide pharmaceutical active ingredient and / or intermediate passports or digital assets to a decentralized network in association with the produced pharmaceutical active ingredient and / or intermediate, wherein environmental attributes associated with the pharmaceutical active ingredient and / or intermediate are made accessible to consumers of the pharmaceutical active ingredient and / or intermediate via the pharmaceutical active ingredient and / or intermediate passport or digital assets.

[0009] In another embodiment, a method for generating a pharmaceutical active ingredient and / or intermediate passport or digital asset associated with a pharmaceutical active ingredient and / or intermediate thereof is disclosed, for example, a computer implementation method, wherein the pharmaceutical active ingredient and / or intermediate thereof is produced from one or more input materials through one or more chemical processes of a chemical production network, and one or more input materials and / or one or more chemical processes are associated with environmental attributes, and the method is - To provide a distributed identifier associated with the produced pharmaceutical active ingredient and / or intermediate thereof, and one or more environmental attributes of one or more input materials and / or one or more chemical processes used to produce the pharmaceutical active ingredient and / or intermediate thereof, - Linking distributed identifiers with environmental attributes, - Providing a pharmaceutical active ingredient and / or intermediate passport or digital asset to a decentralized network in association with the produced pharmaceutical active ingredient and / or intermediate, wherein environmental attributes associated with the pharmaceutical active ingredient and / or intermediate are made accessible to users of the pharmaceutical active ingredient and / or intermediate via the pharmaceutical active ingredient and / or intermediate passport or digital asset.

[0010] In another embodiment, a computer element is disclosed, such as a computer-readable storage medium, a computer program, or a computer program product, which, when executed by a computing node or computing system, includes instructions that instruct the computing node or computing system to perform steps of a computer implementation method disclosed herein.

[0011] In another embodiment, a computer element is disclosed, such as a computer-readable storage medium, a computer program, or a computer program product, which, when executed by the apparatus disclosed herein, includes instructions that instruct the apparatus to perform steps configured to be performed by the apparatus disclosed herein.

[0012] In another embodiment, a pharmaceutical active ingredient and / or its intermediates associated with a passport and digital assets, produced according to the method disclosed herein, is disclosed. In another embodiment, a pharmaceutical active ingredient and / or its intermediates associated with a passport and digital assets, produced according to the system disclosed herein, is disclosed.

[0013] In another embodiment, a pharmaceutical active ingredient and / or intermediate associated with a pharmaceutical active ingredient and / or intermediate passport or digital asset is disclosed, wherein the pharmaceutical active ingredient and / or intermediate is produced from one or more input materials via one or more chemical processes of a chemical production network, the one or more input materials and / or one or more chemical processes are associated with environmental attributes, and the pharmaceutical active ingredient and / or intermediate passport or digital asset includes a distributed identifier associated with the produced pharmaceutical active ingredient and / or intermediate, and a link to environmental attributes associated with one or more environmental attributes of the one or more input materials and / or one or more chemical processes used in the production of the pharmaceutical active ingredient and / or intermediate.

[0014] In another embodiment, a pharmaceutical active ingredient and / or its intermediate passport or digital asset produced in accordance with the method disclosed herein is disclosed. In another embodiment, a pharmaceutical active ingredient and / or its intermediate passport or digital asset produced in accordance with the apparatus disclosed herein is disclosed.

[0015] In another embodiment, a production system for producing products from pharmacovigilants and / or their intermediates associated with a pharmacovigilant and / or its intermediates passport or digital asset is disclosed, provided according to the system, apparatus, or method disclosed herein. In another embodiment, a production method for producing products from pharmacovigilants and / or their intermediates associated with a pharmacovigilant and / or its intermediates passport or digital asset is disclosed, provided according to the system, apparatus, or method disclosed herein.

[0016] In another embodiment, the use of the pharmacovigilants and / or intermediates associated with the pharmacovigilants and / or intermediates passport or digital asset disclosed herein is disclosed for producing products from the pharmacovigilants and / or intermediates associated with the pharmacovigilants and / or intermediates passport or digital asset.

[0017] In another embodiment, the use of the pharmacovigilant active ingredient and / or intermediate passport or digital asset disclosed herein is disclosed for generating a product passport or digital asset associated with a product produced from the pharmacovigilant active ingredient and / or intermediate associated with the pharmacovigilant active ingredient and / or intermediate passport or digital asset. In another embodiment, a method is disclosed for using a digital asset generated according to the method disclosed herein in the production of a product produced from the pharmacovigilant active ingredient and / or intermediate associated with the pharmacovigilant active ingredient and / or intermediate passport or digital asset.

[0018] In another embodiment, a pharmaceutical active ingredient and / or intermediate is disclosed, which is associated with a digital asset that includes a distributed identifier linked to one or more environmental attributes of one or more input materials and / or one or more chemical processes used to produce the pharmaceutical active ingredient and / or intermediate.

[0019] In another aspect, there is disclosed a use of an active pharmaceutical ingredient and / or its intermediate, associated with an active pharmaceutical ingredient and / or its intermediate passport or digital asset, for producing a product from the active pharmaceutical ingredient and / or its intermediate and associating the active pharmaceutical ingredient and / or its intermediate passport or digital asset with the product produced from the active pharmaceutical ingredient and / or its intermediate. In another aspect, there is disclosed a use of an active pharmaceutical ingredient and / or its intermediate, associated with an active pharmaceutical ingredient and / or its intermediate passport or digital asset, for producing a product from the active pharmaceutical ingredient and / or its intermediate and deriving a product passport or digital asset from the active pharmaceutical ingredient and / or its intermediate passport or digital asset. In another aspect, there is disclosed a method of using an active pharmaceutical ingredient and / or its intermediate, associated with a digital asset, for producing a product from the active pharmaceutical ingredient and / or its intermediate disclosed herein and deriving a digital asset associated with the product from the active pharmaceutical ingredient and / or its intermediate passport or digital asset.

[0020] Any disclosure and embodiment described herein relate to the methods, systems, chemical products, active pharmaceutical ingredients and / or their intermediates, active pharmaceutical ingredients and / or their intermediate passports or digital assets, and computer elements outlined above and below. Advantageously, the benefits provided by any of the embodiments and examples apply equally to all other embodiments and examples.

[0021] Embodiment The following is an overview of embodiments of the present disclosure, outlined using embodiments and / or examples. It should be understood that the present disclosure is not limited to the above embodiments and / or examples.

[0022] Determination, generation includes the start or occurrence of the determination, generation. Providing includes "the start or occurrence of access, determination, generation, transmission, or reception". "The start or occurrence of an action" includes any process signal that activates a computing node that performs each action.

[0023] The methods, systems, active pharmaceutical ingredients and / or intermediates, active pharmaceutical ingredient and / or intermediate passports or digital assets, and computer elements disclosed herein provide an efficient, secure, and robust way to share or exchange environmental impact data across different stakeholder nodes in a value chain. Specifically, by providing specific data on active pharmaceutical ingredients and / or intermediates via active pharmaceutical ingredient and / or intermediate passports or digital assets, environmental impacts can be shared and made transparent from the active pharmaceutical ingredients and / or intermediates to the products produced from such active pharmaceutical ingredients and / or intermediates. Active pharmaceutical ingredient and / or intermediate passports or digital assets enable secure data exchange because data access can be controlled by the provider of the active pharmaceutical ingredient and / or intermediate, for example, the entity that provides the active pharmaceutical ingredient and / or intermediate. The data assets exchanged may be specific to the active pharmaceutical ingredient and / or intermediate, produced and tailored to the needs of the customer and / or consumer of the active pharmaceutical ingredient and / or intermediate. In this way, by securely providing environmental impact data across diverse and highly complex value chains, improved tracking and tracing of pharmaceutical active ingredients and / or their intermediates can be achieved. Consequently, the environmental impacts of pharmaceutical active ingredients and / or their intermediates can be tracked, leading to easier, more efficient, and sustainable handling of pharmaceutical active ingredients and / or their intermediates by value chain stakeholders.

[0024] Pharmaceutical active ingredients are substances that provide pharmacological activity or other direct effects in the diagnosis, cure, alleviation, treatment, or prevention of disease, or that affect the structure or any function of the body. Their intermediates are isolated products generated during the multi-step synthesis pathway of pharmaceutical active ingredients.

[0025] Examples of active pharmaceutical ingredients and / or intermediates associated with a passport or digital asset include, but are not limited to, substances that affect hyperpigmentation, rosacea (azelaic acid), wound healing (dexpanthenol), or substances that act as preservatives, disinfectants (poly[(2-oxopyrrolidine-1yl)ethylene]iodine), topical analgesics, topical anesthetics (L-menthol), and nonsteroidal anti-inflammatory drugs (ibuprofen, ibuprofen sodium dihydrate, racemic ibuprofen licinate), or intermediates for producing certain active ingredients such as 4-hydroxyacetophenone or 2-hydroxyacetophenone.

[0026] The active pharmaceutical ingredient and / or intermediate thereof may be selected from, for example, the following list:

[0027] [Table 1]

[0028] A chemical production network may include one or more chemical and / or mechanical processes. A chemical production network may produce one or more output materials through chemical and / or mechanical processing. A chemical production network may include multiple types of production processes for producing one or more output materials from one or more input materials. A chemical production network may produce one or more output materials from input materials supplied to the chemical production network. A chemical production network may include a complex production network that produces multiple chemical products through multiple production processes. A chemical production network may include connected, interconnected, and / or unconnected production processes. A chemical production network may include a composite network or a Verbund network.

[0029] A chemical production network may include identity preservation or separation production processes. In this context, identity preservation or separation may refer to the preservation or separation of environmental attributes of input materials in the production process. Examples include non-fossil, such as renewable or recycled input materials, used to produce one or more active pharmaceutical ingredients and / or intermediates thereof. A further example is fossil input materials used to produce one or more active pharmaceutical ingredients and / or intermediates thereof that contain fossils. A chemical production network may include non-identity preservation or non-separation production processes. In this context, non-identity preservation or non-separation may refer to the mixing of non-fossil input materials with fossil input materials in order to produce active pharmaceutical ingredients and / or intermediates thereof. For example, fossil and renewable input materials may be mixed to produce active pharmaceutical ingredients and / or intermediates thereof that contain fossil and renewable components.

[0030] A chemical production network may include one or more production processes having multiple production steps. The production steps included in a chemical network may be defined by the physical system boundary of the chemical production network. The system boundary may be defined by the location and / or control of the production process or step. The system boundary may be defined by the locations of the chemical production network. The system boundary may be defined by a production process or step jointly controlled by one or more entities. The system boundary may be defined by a value chain having time-staggered production processes or steps to a final chemical product, which may be jointly or individually controlled by multiple entities. A chemical production network may include waste recovery, sorting steps, recycling steps such as pyrolysis, cracking steps such as steam cracking, separation steps to separate intermediates from one process step, and further processing steps to convert such intermediates, particularly produced pharmaceutical active ingredients and / or their intermediates discharged from the system boundary of the chemical production network, into output materials. Input materials may enter the physical system boundary of the chemical production network. An entry point to a chemical production network may be indicated by the input of input materials into the chemical production network or the system boundary of the chemical network. The output materials, in particular the produced pharmaceutical active ingredients and / or intermediates, may be discharged from the physical system boundary of the chemical production network. The exit point of the chemical production network may be indicated by the output materials, in particular the produced pharmaceutical active ingredients and / or intermediates, leaving the chemical production network or the system boundary of the chemical network.

[0031] A chemical production network may include one or more production chains for the production of pharmaceutical active ingredients and / or intermediates thereof. Production chains for the production of pharmaceutical active ingredients and / or intermediates may be interconnected. Production chains for the production of pharmaceutical active ingredients and / or intermediates may be interconnected with production chains for the production of other output materials. A production chain for the production of pharmaceutical active ingredients and / or intermediates may include production chains for the production of intermediates used to produce pharmaceutical active ingredients and / or intermediates. A production chain for the production of pharmaceutical active ingredients and / or intermediates may use input materials supplied by the chemical network for the production of intermediates that can be used to produce pharmaceutical active ingredients and / or intermediates.

[0032] One or more input materials may be supplied to a chemical production network for the production of one or more output materials, in particular active pharmaceutical ingredients and / or their intermediates. The output materials, in particular active pharmaceutical ingredients and / or their intermediates, may be produced from one or more input materials through one or more chemical processes in the chemical production network. Input materials may include any input materials that enter the chemical production network at any entry point. Input materials may include organic or inorganic input materials. Input materials may be precursor products, intermediate materials, feedstocks, or raw materials used to produce one or more output materials, in particular active pharmaceutical ingredients and / or their intermediates. Input materials may be supplied to a chemical production network for the production of one or more output materials, in particular active pharmaceutical ingredients and / or their intermediates. Input materials may be supplied to a chemical production network that includes one or more production processes having multiple process steps. Input materials may be supplied to the chemical production network at the start of a production process or at any intermediate stage of a production process. Input materials entering the chemical production network may be used to produce one or more output materials, in particular active pharmaceutical ingredients and / or their intermediates.

[0033] An input material can be associated with an input material identifier. An input material identifier may include any identifier uniquely associated with the input material. An input material identifier may be associated with the physical entity of the input material. An input material identifier may be associated with a single batch of input material. An input material identifier may be associated with a group of input materials. An identifier may be associated with multiple physical entities of the input material. An input material identifier may be associated with a continuous or semi-continuous stream of input material. For example, an input material identifier may be associated with a stream of input material over a specific period or from a specific supplier. An input material identifier may be linked to or connected to one or more environmental attributes.

[0034] Environmental attributes can refer to characteristics related to environmental impacts. Such characteristics may be those of input materials, chemical processes, chemical production networks, and / or active pharmaceutical ingredients and / or their intermediates. Environmental attributes can indicate the environmental performance of input materials, chemical processes, chemical production networks, and / or active pharmaceutical ingredients and / or their intermediates. Environmental attributes can be derived from the characteristics of input materials, chemical processes, chemical production networks, and / or active pharmaceutical ingredients and / or their intermediates. Environmental attributes can be associated with the environmental impacts of input materials, chemical processes, chemical production networks, and / or active pharmaceutical ingredients and / or their intermediates at any stage of the lifecycle of input materials, and / or active pharmaceutical ingredients and / or their intermediates. Stages may include supplying raw materials, supplying raw materials, producing chemical products such as intermediate or final products, producing individual products by using chemical products, using chemical products or individual products, processing used products, recycling used products, disposing of used products, reusing components from used products, or any subset of stages. Environmental attributes may be specified or derived from any activity of one or more entities involved at any stage in the lifecycle of one or more materials or products.

[0035] Environmental attributes may include one or more characteristics that can be linked to the environmental impact of input materials, chemical processes, chemical production networks, and / or pharmaceutical active ingredients and / or their intermediates. Environmental attributes may include environmental characteristics, technical characteristics, recyclability characteristics, or circularity characteristics associated with the environmental impact of input materials, chemical processes, chemical production networks, and / or pharmaceutical active ingredients and / or their intermediates.

[0036] Environmental attributes may include one or more characteristics that can be linked to the environmental impacts of input materials, chemical processes, chemical production networks, and / or active pharmaceutical ingredients and / or their intermediates. Environmental attributes may include environmental characteristics, technical characteristics, recyclability characteristics, or circular characteristics associated with the environmental impacts of input materials, chemical processes, chemical production networks, and / or active pharmaceutical ingredients and / or their intermediates. One or more environmental attributes may be linked to the environmental impacts of active pharmaceutical ingredients and / or their intermediates. One or more environmental attributes may be related to the environmental, technical, recyclability, circularity, and / or complementary risk characteristics of active pharmaceutical ingredients and / or their intermediates.

[0037] Environmental characteristics may specify or quantify ecological criteria associated with environmental impacts. Environmental characteristics may be measurements taken during the life cycle or may be derived from such measurements. Environmental characteristics may be determined at any stage of the life cycle and may characterize environmental impacts across or up to such stages. Environmental characteristics may include, for example, carbon footprint, greenhouse gas emissions, resource use, atmospheric emissions, ozone depletion potential, water pollution, noise pollution, energy consumption, waste reduction, or eutrophication potential. Environmental characteristics may include, for example, product characteristics relating to the production of products such as biological, plant-based, animal-based, halogen-free, fluorine-free, vegan, halal, kosher, palm oil-free, natural, hazardous substance-free, volatile organic compound-free, or any combination thereof.

[0038] Technical characteristics can specify or quantify performance that is at least indirectly related to environmental impact. Technical characteristics may be measurements taken during the lifecycle, or can be derived therefrom. Technical characteristics may be determined at any stage of the lifecycle and may characterize performance over or up to such stages. Technical characteristics may include, for example, raw material composition such as chemical composition data, such as bio-based or recycled input material content specifying x% non-fossil content and y% fossil content, material lists, product purity, product form (as an indicator of their impact on dust formation / emission), product specification data such as safety data, product extractability, migration data, toxicological data or ecotoxicity data, product component data, safety data, application characteristics data, application instructions, quality data, or any combination thereof.

[0039] Circular characteristics can specify or quantify lifecycle characteristics associated with recyclable use. Circular characteristics may be measurements taken during the lifecycle, or can be derived from them. Circular characteristics may be recyclable data recorded in one or more previous lifecycles, including reuse, or can be derived from them. Circular characteristics may be determined at any stage of the lifecycle and may characterize reuse or recycling performance across or up to such stages. Circular characteristics may include, for example, recycling data, reuse rate, recycling rate, recycling loop, reuse performance, reuse quality, or any combination thereof.

[0040] Recyclability characteristics can identify or quantify life cycle characteristics associated with recycling. Recyclability characteristics may include the composition of a material, including specially formulated components that make the material suitable for recycling. Recyclability characteristics may be measurements taken during the life cycle, or can be derived therefrom. Recyclability characteristics may be recycling data recorded in one or more previous life cycles, or can be derived therefrom. Recyclability characteristics may be determined at any stage of the life cycle and may characterize the recycling performance over or up to such stages. Recyclability characteristics may include, for example, recycling data, reuse count, recycled material composition, recycled material quality, waste flow composition, waste flow quality, or any combination thereof.

[0041] In one embodiment, a pharmaceutical active ingredient and / or intermediate passport or digital asset associated with a pharmaceutical active ingredient and / or intermediate may include a material balance environmental attribute related to the input materials. This material balance environmental attribute may include the environmental attributes of the input materials used to produce the pharmaceutical active ingredient and / or intermediate, which are trackable and can be linked to the pharmaceutical active ingredient and / or intermediate by mass. The environmental impact of the input materials may be determined based on the input materials used in the chemical process for producing the pharmaceutical active ingredient and / or intermediate. For example, the bio-based, renewable, and / or recycled content of the input materials used to produce the pharmaceutical active ingredient and / or intermediate may be tracked. Furthermore, for example, the biomethane content of the input materials used to produce the pharmaceutical active ingredient and / or intermediate may be tracked.

[0042] Furthermore, for example, the environmental impact characteristics of input materials, including biomethane, can be tracked. Additionally, for example, the characteristics of chemical processes used to produce pharmaceutical active ingredients and / or intermediates can be tracked. Examples of tracked process characteristics related to environmental impact include water consumption, CO2 emissions and / or greenhouse gas (GHG) emissions, waste generation, mixed material generation, recycling design, energy consumption, and treatment characteristics such as less waste or less characteristic loss. Characteristics can be tracked based on certificates from accredited bodies. Characteristics can also be tracked based on inherent physical characteristics derived from measured values.

[0043] In one embodiment, the produced active pharmaceutical ingredient and / or intermediate is linked to a distributed identifier that physically identifies the produced active pharmaceutical ingredient and / or intermediate. The production operating device may be configured to provide a distributed identifier associated with the physical entity of the produced active pharmaceutical ingredient and / or intermediate. The production operating device may be configured to link the distributed identifier to the physical identifier of the produced active pharmaceutical ingredient and / or intermediate. The production operating device may be configured to assign the distributed identifier to the physical identifier linked to the produced active pharmaceutical ingredient and / or intermediate. The production operating device may be configured to assign the distributed identifier to the physical identifier physically linked to the produced active pharmaceutical ingredient and / or intermediate.

[0044] In one embodiment, the distributed identifier relates to data associated with at least one product produced from a pharmaceutical active ingredient and / or its intermediates, and one or more environmental attributes associated with at least one product are derived from one or more environmental attributes associated with the pharmaceutical active ingredient and / or its intermediates. One or more environmental attributes associated with the pharmaceutical active ingredient and / or its intermediates may be associated with one or more input materials and / or chemical processes used to produce the pharmaceutical active ingredient and / or its intermediates. The distributed identifier may be associated with any identifier uniquely associated with the pharmaceutical active ingredient and / or its intermediates. The distributed identifier may be associated with the physical entities of the pharmaceutical active ingredient and / or its intermediates. The distributed identifier may refer to a single batch of the pharmaceutical active ingredient and / or its intermediates. The distributed identifier may be associated with a group of pharmaceutical active ingredients and / or its intermediates. The identifier may refer to multiple physical entities of the pharmaceutical active ingredient and / or its intermediates. The distributed identifier may be associated with a continuous or semi-continuous stream of the pharmaceutical active ingredient and / or its intermediates. The identifier may, for example, refer to a stream of pharmaceutical active ingredients and / or intermediates over a specific period or from a specific supplier.

[0045] In one embodiment, one or more environmental attributes associated with a pharmaceutical active ingredient and / or its intermediates are provided from at least one balance account configured to store environmental attributes associated with input materials. The balance account may be associated with a storage structure associated with metadata such as environmental attribute types. For example, the balance account may be associated with metadata indicating that the environmental attribute type is recycled material content or bio-based material content. An inbound allocator may be configured to allocate one or more environmental attributes associated with input materials to at least one balance account when input materials are introduced into a chemical production network, for example. The balance account may be associated with each environmental attribute type. An outbound assigner may be configured to assign at least one environmental attribute from at least one balance account associated with each environmental attribute to a distributed identifier. One or more environmental attributes may be assigned to at least one distributed identifier. The assignment may include deallocating one or more environmental attributes from the balance account associated with each environmental attribute type. By using balance accounts, environmental attributes of input materials can be reliably tracked and assigned to pharmaceutical active ingredients and / or their intermediates.

[0046] In one embodiment, one or more environmental attributes associated with a pharmaceutical active ingredient and / or its intermediates are provided from at least one balance account configured to store environmental attributes associated with input materials. An inbound allocator may be configured, for example, to allocate one or more environmental attributes to at least one balance account associated with each environmental attribute when the input materials are introduced into the chemical production network. Balance accounts may be associated with each environmental attribute type. One or more environmental attributes associated with input materials may be allocated to balance accounts associated with each environmental attribute type. An outbound assigner may be configured to assign or link at least one environmental attribute from at least one balance account associated with each environmental attribute type to a distributed identifier. This may include deallocating one or more environmental attributes from balance accounts associated with each environmental attribute type. By using balance accounts, environmental attributes can be retained throughout the chemical production network. In this way, environmental attributes can be decoupled from the material flow. The linking of environmental attributes may be based on the material balance of the chemical production network. In such a method, the total mass of the input materials, active pharmaceutical ingredients, and / or their intermediates, as well as the association of each environmental attribute associated with the input materials, active pharmaceutical ingredients, and / or their intermediates, are balanced.

[0047] In one embodiment, one or more environmental attributes are associated with at least one characteristic relating to the environmental impact of one or more input materials and / or chemical processes. One or more environmental attributes may specify the environmental characteristics of input materials used to produce pharmaceutical active ingredients and / or intermediates thereof, and / or one or more environmental attributes may specify the environmental characteristics of chemical processes used to produce pharmaceutical active ingredients and / or intermediates thereof. One or more environmental attributes may be generated from the environmental characteristics of input materials used to produce pharmaceutical active ingredients and / or intermediates thereof, process data associated with the chemical treatment of input materials, and / or energy data associated with the energy consumption of the chemical treatment. One or more environmental attributes may include recycled material content associated with input materials that is allocated or can be allocated to pharmaceutical active ingredients and / or intermediates, renewable material content associated with input materials that is allocated or can be allocated to pharmaceutical active ingredients and / or intermediates, and / or product carbon footprint associated with pharmaceutical active ingredients and / or intermediates.

[0048] In one embodiment, the production operating device is configured to collect environmental attributes associated with the pharmaceutical active ingredients and / or intermediates to be produced before, during, and / or after production of the pharmaceutical active ingredients and / or intermediates by the chemical production network. The environmental attributes associated with the pharmaceutical active ingredients and / or intermediates to be produced may relate to input materials. Environmental attributes associated with input materials may be provided before, during, and / or after production of the pharmaceutical active ingredients and / or intermediates by the chemical production network. Environmental attributes associated with input materials may be allocated to at least one balance account before, during, and / or after production of the pharmaceutical active ingredients and / or intermediates by the chemical production network. The environmental attributes associated with the pharmaceutical active ingredients and / or intermediates to be produced may relate to environmental characteristics generated from process data associated with the chemical processing of input materials and / or energy data associated with the energy consumption of the chemical processing. Environmental attributes associated with the pharmaceutical active ingredients and / or intermediates to be produced may be generated before, during, and / or after production of the pharmaceutical active ingredients and / or intermediates by the chemical production network. Process data associated with the chemical treatment of input materials, and / or energy data associated with the energy consumption of the chemical treatment, may be collected before, during, and / or after the production of pharmaceutical active ingredients and / or their intermediates.

[0049] In one embodiment, a pharmaceutical active ingredient and / or its intermediate passport or digital asset may include a distributed identifier associated with the pharmaceutical active ingredient and / or its intermediate, and one or more environmental attributes linked to the distributed identifier. One or more environmental attributes may be linked to a distributed identifier contained in the pharmaceutical active ingredient and / or its intermediate passport or digital asset. One or more environmental attributes may be stored in a database associated with the pharmaceutical active ingredient and / or its intermediate producer or in the pharmaceutical active ingredient and / or its intermediate producer's database for access by any consumer and / or customer of the pharmaceutical active ingredient and / or its intermediate. One or more environmental attributes may be stored in a database associated with the pharmaceutical active ingredient and / or its intermediate producer or in the pharmaceutical active ingredient and / or its intermediate producer's database for transfer to consumers and / or customers of the pharmaceutical active ingredient and / or its intermediate, for example, when accessed or when the pharmaceutical active ingredient and / or its intermediate is provided. The distributed identifier may include any unique identifier uniquely associated with the pharmaceutical active ingredient and / or its intermediate producer, as well as pharmaceutical active ingredient and / or its intermediate data such as environmental attributes. A distributed identifier may include a universally unique identifier (UUID) or a digital identifier (DID). A distributed identifier may be issued by a central or distributed identity issuer. A distributed identifier may be linked to authentication and / or authorization information. Access to the active pharmaceutical ingredient and / or intermediate data may be controlled by the active pharmaceutical ingredient and / or intermediate producer through a unique association of the distributed identifier with the active pharmaceutical ingredient and / or intermediate producer, as well as with the active pharmaceutical ingredient and / or intermediate data, such as environmental attributes. This is in contrast to a centralized authority system, where the identifier is provided by such centralized authority and access to the data is controlled by such centralized authority. In this context, distributed refers to the use of identifiers in implementations controlled by data owners, such as the active pharmaceutical ingredient and / or intermediate producer.

[0050] A distributed identifier may be uniquely associated with a pharmaceutical active ingredient and / or its intermediates, or with a physical entity of a pharmaceutical active ingredient and / or its intermediates packaged for transport to consumers and / or customers, for example. A distributed identifier may be unique for one or more environmental attributes. A pharmaceutical active ingredient and / or its intermediate passport or digital asset may include one or more digital representations that point to pharmaceutical active ingredient and / or its intermediate data including environmental attributes, or a portion of pharmaceutical active ingredient and / or its intermediate data including environmental attributes. A digital representation may have at least one interface to a data delivery service. A digital representation may further include at least one interface to a data consumption service. A digital representation may include an endpoint for data exchange or sharing (resource endpoint) or an endpoint for service interaction (service endpoint) that is uniquely identified via a communication protocol. A digital representation that points to pharmaceutical active ingredient and / or its intermediate data, or a portion thereof, may be uniquely associated with a distributed identifier.

[0051] A pharmaceutical active ingredient and / or intermediate passport or digital asset may include or be linked to a digital representation of pharmaceutical active ingredient and / or intermediate data, such as environmental attributes. The digital representation may include a representation for accessing pharmaceutical active ingredient and / or intermediate data, such as environmental attributes or a portion thereof. The digital representation may include a representation of pharmaceutical active ingredient and / or intermediate data, such as environmental attributes. A pharmaceutical active ingredient and / or intermediate passport or digital asset may include or be linked to pharmaceutical active ingredient and / or intermediate data, such as environmental attributes, authentication information, and distributed identifiers. Data related to pharmaceutical active ingredient and / or intermediate data, such as environmental attributes, may include a digital representation of pharmaceutical active ingredient and / or intermediate data, such as environmental attributes.

[0052] The present disclosure will be further described below with reference to the attached drawings. [Brief explanation of the drawing]

[0053] [Figure 1] An example of a chemical production network that produces one or more output materials from one or more input materials is schematically shown in relation to a production operating system that includes an attribute management system. [Figure 2] A schematic example of linking the environmental attributes of input materials to the output materials of a chemical production network is shown. [Figure 3] A schematic example of linking the environmental attributes of input materials and chemical processes to the output materials of a chemical production network is shown. [Figure 4] Another schematic example of a method or apparatus for providing environmental attributes associated with produced materials to material users as data consumers via a distributed network is schematically shown. [Figure 5] A schematic example of a method or apparatus for providing environmental attributes of output materials across the entire value chain via a distributed network is schematically shown. [Figure 6] A schematic example of a chemical production network for producing pharmaceutical active ingredients and / or intermediates associated with digital assets is shown. [Modes for carrying out the invention]

[0054] Figure 1 shows one embodiment of a chemical production network 102 that produces one or more output materials, in particular a pharmaceutical active ingredient and / or intermediate 104, from one or more input materials 100, in relation to a production operating system 106 including an attribute management system.

[0055] Various input materials 100 may be provided to the chemical production network 102 as physical inputs to produce one or more output materials, in particular pharmaceutical active ingredients and / or their intermediates 104. The physical input materials 100 and the output materials, in particular pharmaceutical active ingredients and / or their intermediates 104, may be associated with one or more properties related to environmental impact. Properties related to environmental impact may be digitized in the form of environmental attributes, such as the recycled material content or bio-based material content of the input materials. The production operating system 106 may be configured to take in such environmental attributes and track them throughout the chemical production network 102, from the input materials 100 to the output materials, in particular pharmaceutical active ingredients and / or their intermediates 104.

[0056] The chemical production network 102 may include a plurality of interconnected processing steps. The chemical production network 102 may be an integrated chemical production network 102 having interconnected production chains. The chemical production network 102 may include a plurality of different production chains having at least one common intermediate product. The chemical production network 102 may include a plurality of stages in a chemical value chain. The chemical production network 102 may include the production, refining, processing, and / or purification of gas or crude oil. The chemical production network 102 may include a synthesis gas plant connected to a plurality of production chains that produce product 104 from a stream cracker or the effluent of such a plant. The chemical production network 102 may include a plurality of production chains that produce one or more output materials, in particular pharmaceutical active ingredients and / or intermediates 104, from one or more input materials 100. The chemical production network 102 may include a plurality of hierarchies in a chemical value chain. The chemical production network 102 may include the arrangement of physically interconnected production sites. The production sites may be in the same location or in different locations. In the latter case, production sites may be interconnected by dedicated transportation systems such as pipelines, supply chain vehicles such as trucks, supply chain vessels, or other means of freight transport.

[0057] The chemical production network 102 can chemically convert input materials 100 into one or more output materials, particularly active pharmaceutical ingredients and / or intermediates thereof 104.

[0058] The input material 100 can be supplied to the chemical production network 102 at any inlet point. The input material 100 can also be supplied to the chemical production network 102 at the start of the chemical production network 102. The input material 100 can, for example, constitute the raw materials for a steam cracker. The input material 100 may include non-fossil input materials such as bio-based materials or recycled materials, and / or fossil input materials for the production of chemical intermediates and chemical output materials, in particular active pharmaceutical ingredients and / or their intermediates 104.

[0059] The chemical production network 102 may include multiple production steps. The production steps included in the chemical production network 102 may be defined by the system boundary of the chemical production network 102. The system boundary may be defined by the location or control of the production process. The system boundary may be defined by the sites of the chemical production network 102. The system boundary may be defined by a production process jointly controlled by one entity or multiple entities. The system boundary may be defined by a value chain having a time-staggered production process to the final product, and this value chain may be individually controlled by multiple entities. The chemical production network 102 may include a waste recovery and sorting step, a recycling step such as pyrolysis, a cracking step such as steam cracking, a separation step for separating an intermediate of one process step, and a further processing step for converting such intermediate into output material, in particular a pharmaceutical active ingredient and / or its intermediate 104, exiting the system boundary of the chemical production network 102.

[0060] The production operating system 106 of the chemical production network 102 may be configured to monitor and / or control the chemical production network 102 based on the operating parameters of different processes. One process step to be monitored and / or controlled may be the supply of input materials 100 or the release of output materials, in particular active pharmaceutical ingredients and / or their intermediates 104. Another process step to be monitored and / or controlled may be the registration of environmental attributes associated with input materials 100 entering the system boundary of the chemical production network 102. Yet another process step to be monitored and / or controlled may be the association of environmental attributes with output materials, in particular active pharmaceutical ingredients and / or their intermediates 104 produced through the chemical production network 102. Yet another process step to be monitored and / or controlled may be the management of environmental attributes associated with input materials 100 and output materials, in particular active pharmaceutical ingredients and / or their intermediates 104 of the chemical production network 102.

[0061] The production operating system 106 may be configured to register inbound environmental attributes and assign outbound environmental attributes. The production operating system 106 may be configured to access data related to input materials 100, processes, and / or output materials used in the chemical production network 102, particularly active pharmaceutical ingredients and / or their intermediates 104. For example, the production operating system 106 may be configured to register the recycled material content or bio-based material content of one or more input materials 100 used in the chemical production network 102 as an environmental attribute. The production operating system 106 may be configured to allocate the environmental attribute to at least one balance account associated with the recycled material content or bio-based material content of the input material 100. The production operating system 106 may be configured to allocate at least a portion of the environmental attributes from at least one balance account to at least one output material, particularly active pharmaceutical ingredients and / or their intermediates 104.

[0062] The production operating system 102 may be configured to handle environmental attributes related to the input materials 100 of the chemical production network 102, as well as the output materials, particularly active pharmaceutical ingredients and / or their intermediates 104. For example, the production operating system 106 may be configured to determine environmental attributes associated with the use of input materials 100 that affect the environmental characteristics of the chemical production network 102, as well as the output materials produced by the chemical production network 102, particularly active pharmaceutical ingredients and / or their intermediates 104. Furthermore, the production operating system 102 may be configured to determine environmental attributes associated with the output materials, particularly active pharmaceutical ingredients and / or their intermediates 104. In this way, the production operating system 102 may be configured to store environmental attributes in a balance account or to withdraw environmental attributes from a balance account. Thus, environmental attributes can be considered as credits that can be deposited into or withdrawn from accounts related to the input materials of the chemical production network 102, as well as the output materials, particularly active pharmaceutical ingredients and / or their intermediates. In this way, the environmental impact of production can be traced and / or retroactive.

[0063] In the chemical production network 102, multiple value chains may be linked. In addition, different input materials 100 or chemical processes may be used that affect the environmental properties of the output materials produced by the chemical production network 102, particularly pharmaceutical active ingredients and / or their intermediates 104. Examples of input materials 100 that affect at least one environmental property of the output materials produced from such input materials 100, particularly pharmaceutical active ingredients and / or their intermediates 104, include recycled, renewable, or bio-based input materials 104. Examples of chemical processes that affect environmental properties include chemical processes that use environmentally friendly technologies such as carbon capture, carbon utilization, or heat pumps.

[0064] Due to the processing of chemicals in continuous or semi-continuous production and the complexity of the chemical production network 102, traceability of input materials through the network may be hindered. In such scenarios, equivalent environmental attributes that indicate the impact on the environmental properties of the output materials produced by the chemical production network, particularly active pharmaceutical ingredients and / or their intermediates 104, may be allocated to balance accounts and assigned to one or more output materials of the chemical production network 102, particularly active pharmaceutical ingredients and / or their intermediates 104. Environmental attributes can therefore be separated from the physical material flow within the chemical production network 102. The separation may be based on a mass balance model in which the equivalents assigned to one or more output materials, particularly active pharmaceutical ingredients and / or their intermediates, may not exceed the equivalents provided by the input materials or processes. If equivalents are allocated to a virtual account of one environmental attribute type, they may not be allocated a second time to another virtual account of the same environmental attribute type. Environmental attribute types may include recycled, bio-based, renewable, etc. Environmental attributes may be provided in the form of digital assets associated with the physical entities of pharmaceutical active ingredients and / or their intermediates, or as pharmaceutical active ingredient and / or their intermediate passports.

[0065] Figure 2 schematically shows one example in which environmental attributes associated with input materials 100 are linked to output materials, particularly pharmaceutical active ingredients and / or their intermediates 104 in the chemical production network 102.

[0066] As shown in Figure 1, the chemical production network 102 and its operation can be monitored and / or controlled by a production operating system 106. The production operating system 106 may be configured to track environmental attributes from the input materials 100 supplied to the chemical production network 102 to the output materials produced by the chemical production network 102, in particular active pharmaceutical ingredients and / or their intermediates 104. For tracking purposes, the operating system 106 may be configured to register environmental attributes associated with the input materials 100 supplied to the chemical production network 102 and to link these environmental attributes to the output materials produced by the chemical production network 102, in particular active pharmaceutical ingredients and / or their intermediates 104.

[0067] Input materials 100, such as pyrolysis oil, bionaphtha, or biogas, may be supplied to a chemical production network 102. The input materials 100 may enter the chemical production network 104 at an inlet point such as a steam cracker or a synthesis gas plant. The input materials 100 may be used in the chemical production network 102 to produce one or more output materials, in particular pharmaceutical active ingredients and / or intermediates 104, from the input materials 100, and the output materials, in particular pharmaceutical active ingredients and / or intermediates 104, may be provided at an outlet point of the chemical production network 102. Further output materials may be MDI, TDI, PA6, EPS, PC, polyols, caprolactam, adipic acid, HMD, and polyamides.

[0068] When input material 100 is introduced, input material data 108 may be provided to the computing interface of the production operating system 106 via a communication network. A data provider, such as a QR code® reader, may be configured to provide material data 108 and their respective environmental attributes 108 associated with one or more input materials 100 to the computing interface configured to assign environmental attributes associated with the input materials 100. The material data 108 may include an input material identifier and environmental attributes associated with the input material 100. The input material identifier may be associated with the physical entity of the input material 100 entering the chemical production network 102. The material data may be provided when, before, or after the introduction of one or more input materials at the entry point to the chemical production network 102.

[0069] The input material identifier may be linked to the environmental attributes associated with each input material 100, the quantity of the input material 100, and a certificate certifying the environmental attributes. The quantity of the input material may be the measured amount of the input material 100 supplied to the plant or storage of the chemical production network 102 to produce one or more output materials, in particular a pharmaceutical active ingredient and / or its intermediate 104, from the input material 100. The input material identifier associated with each input material 100, the environmental attributes associated with each input material 100, and the quantity of the input material 100 supplied to the chemical production network 102 may be provided to the production operating system 106. Such data may be provided via a communication network when the input is supplied to the chemical production network 102, or the data may be transferred from a computing system to the production operating system 106.

[0070] The inbound allocator 110 may be configured to allocate one or more environmental attributes to at least one balance account 112 associated with each environmental attribute. For example, one balance account 112 may be associated with environmental attributes from recycled materials, and another balance account 112 may be associated with environmental attributes from bio-based materials. Balance accounts may be associated with each environmental attribute type, such as bio-based or recycled. Based on such associations, balance accounts associated with each environmental attribute type of input material 100 may be selected. Environmental attributes may be allocated to the selected balance account. For example, an account 112 for recycled materials may be selected, and environmental attributes may be allocated to such account 122.

[0071] For allocation, one or more environmental attributes may be converted into balance units, and balance units may be allocated to balance account 122. The conversion may be based on a conversion factor such as mass, weight, carbon atoms, hydrogen atoms, methane equivalent, or any other suitable measure for quantifying the environmental impact of the environmental attribute. The conversion factor may therefore take into account the difference between producing a chemical product from conventional input materials and producing a chemical product from unconventional input materials, or producing a chemical product from a mixture of conventional and unconventional input materials. The conversion factor may relate to the difference in the chemical and / or physical properties of conventional and unconventional input materials.

[0072] By using the balance account 112, it can be ensured that the environmental attributes of input material 100 are used only once for allocation to the active pharmaceutical ingredient and / or its intermediate 104. In this way, double counting of inputs or outputs is avoided, ensuring that positive environmental impacts can be reliably tracked and allocated to the active pharmaceutical ingredient and / or its intermediate 104.

[0073] The identifier provider 116 may be configured to provide identifiers for active pharmaceutical ingredients and / or intermediates associated with active pharmaceutical ingredients and / or intermediates produced by the chemical production network 102 and provided at an exit point from the chemical production network 102.

[0074] The outbound assigner 114 may be configured to assign at least one environmental attribute from at least one balance account 112 associated with each environmental attribute to the active pharmaceutical ingredient and / or intermediate identifier ID2. One or more environmental attributes may be assigned to at least one active pharmaceutical ingredient and / or intermediate identifier ID2. The assignment may include deallocating one or more environmental attributes from the balance account 112 associated with each environmental attribute type. The assignment may include converting one or more balance units into one or more environmental attributes.

[0075] Assigning at least one environmental attribute associated with the input material to the active pharmaceutical ingredient and / or its intermediates may include linking the active pharmaceutical ingredient and / or its intermediate identifier ID2 to the environmental attribute. The active pharmaceutical ingredient and / or its intermediate identifier ID2 may be associated with the physical entity of the active pharmaceutical ingredient and / or its intermediate. In this way, the virtual identifier of the material may be uniquely linked to the physical material. Such a link may include a physical or virtual link of an identifier uniquely associated with the physical material. For a physical link, a tag or code may be physically attached to the material, for example, by printing a QR code (registered trademark) on the package. For a virtual link, various identifiers associated with the physical material may be linked. For example, an order number, batch number, lot number, or a combination thereof may be linked.

[0076] The outbound assigner 114 may be configured to provide environmental attributes associated with the active pharmaceutical ingredient and / or its intermediates to data consumers, such as systems associated with users of the active pharmaceutical ingredient and / or its intermediates. The outbound assigner 114 may be configured to provide environmental attributes associated with the active pharmaceutical ingredient and / or its intermediates to a distributed network, as illustrated in the embodiment of Figure 4. The environmental attributes may be provided in the form of digital assets associated with the physical entities of the active pharmaceutical ingredient and / or its intermediates, or as active pharmaceutical ingredient and / or its intermediate passports, via the ID-based schema described above.

[0077] Figure 3 schematically shows one embodiment in which the input materials 100 and the environmental attributes of the chemical process are linked to the active pharmaceutical ingredients and / or intermediates 104 of the chemical production network 102.

[0078] As illustrated in relation to Figures 1 and 2, the chemical production network 102 and its operation may be monitored and / or controlled by the production operating system 106. Input materials 100, such as pyrolysis oil, bionaphtha, or biogas, may be supplied to the chemical production network 102. The input materials 100 may be used in the chemical production network 102 to produce one or more pharmaceutical active ingredients and / or intermediates 104 from the input materials 100.

[0079] When input material 100 is introduced, input material data 108 may be provided to the computing interface of the production operating system 106 via a communication network. A data provider, such as a QR code® reader, may be configured to provide material data 108 and their respective environmental attributes 108 associated with one or more input materials 100 to the computing interface configured to assign environmental attributes associated with the input materials 100. The material data 108 may include an input material identifier and environmental attributes associated with the input material 100. The input material identifier may be associated with the physical entity of the input material 100 entering the chemical production network 102. The input material identifier may be linked to the carbon footprint of the input material 100 as an environmental attribute. The material data may be provided when, before, or after the introduction of one or more input materials at the entry point to the chemical production network 102.

[0080] The inbound allocator 110 may be configured to read one or more environmental attributes and provide such attributes to the carbon footprint (CF) generator 120. The process data provider 122 may be configured to collect process data associated with the chemical processing of input materials 100 for producing pharmaceutical active ingredients and / or intermediates 104. The process data provider 122 may be configured to collect energy data associated with the energy consumption of the chemical processing. The process data provider 122 may be configured to provide the process data and energy data to the CF generator 120.

[0081] The CF generator 120 may be configured to determine the carbon footprint of pharmaceutical active ingredients and / or intermediates produced by a chemical production network. The carbon footprint of pharmaceutical active ingredients and / or intermediates may be determined based on process data, energy data, and the carbon footprint of input materials 100 used to produce the pharmaceutical active ingredients and / or intermediates.

[0082] The identifier provider 116 may be configured to provide identifiers for active pharmaceutical ingredients and / or intermediates associated with active pharmaceutical ingredients and / or intermediates produced by the chemical production network 102 and provided at an exit point from the chemical production network 102.

[0083] The outbound assignor 114 may be configured to assign the determined carbon footprint to the active pharmaceutical ingredient and / or its intermediate identifier ID2. As illustrated in connection with Figure 2, one or more environmental attributes may be assigned to at least one active pharmaceutical ingredient and / or its intermediate identifier ID2.

[0084] The outbound assigner 114 may be configured to provide environmental attributes, particularly carbon footprint, associated with the active pharmaceutical ingredient and / or its intermediates to data consumers, such as systems associated with users of the active pharmaceutical ingredient and / or its intermediates. The outbound assigner 114 may be configured to provide environmental attributes associated with the active pharmaceutical ingredient and / or its intermediates to a distributed network, as illustrated in the embodiment of Figure 4. The environmental attributes may be provided in the form of digital assets associated with the physical entities of the active pharmaceutical ingredient and / or its intermediates, or as active pharmaceutical ingredient and / or its intermediate passports, via the ID-based schema described above.

[0085] Figure 4 schematically illustrates one embodiment of a method or apparatus for providing environmental attributes associated with pharmaceutical active ingredients and / or intermediates to material users as data consumers via a distributed network.

[0086] The active pharmaceutical ingredients and / or intermediates 104 produced by the chemical production network 102 may be provided in association with digital assets, as described in relation to Figures 2 and 3. The digital assets may include identifiers for the active pharmaceutical ingredients and / or intermediates. The digital assets may include one or more environmental attributes, such as product carbon footprint, recycled material content, or bio-based material content. The digital assets may be associated with one or more environmental attributes, such as product carbon footprint, recycled material content, or bio-based material content. The digital assets may include digital representations of one or more environmental attributes, such as product carbon footprint, recycled material content, or bio-based material content.

[0087] Digital assets may further include, or be associated with, authentication and / or authorization information linked to pharmaceutical active ingredient and / or intermediate identifiers. Authentication and / or authorization information may be provided for authentication and / or authorization of data provision service 208 and / or data consumption service 210. Pharmaceutical active ingredient and / or intermediate identifiers may include, or be associated with, distributed identifiers uniquely associated with pharmaceutical active ingredients and / or intermediates. Distributed identifiers may be linked to digital representations of environmental attributes. Digital representations may include representations for accessing environmental attributes or parts thereof. Distributed identifiers may include universally unique identifiers (UUIDs) or digital identifiers (DIDs). Distributed identifiers may include any unique identifier uniquely associated with the data owner and / or pharmaceutical active ingredient and / or intermediates. The data owner may be the producer of the pharmaceutical active ingredient and / or intermediates. Access to material composition data may be controlled by the data owner through the unique association of the distributed identifier with the data owner and / or the pharmaceutical active ingredient and / or intermediates.

[0088] Digital assets, including digital representations of one or more environmental attributes such as product carbon footprint, recycled material content, or bio-based material content, may be stored in a distributed database 200. One or more environmental attributes such as product carbon footprint, recycled material content, or bio-based material content may also be stored in a database 202 associated with data owners, such as producers of pharmaceutical active ingredients and / or their intermediates 104.

[0089] The active pharmaceutical ingredient and / or its intermediate 104 may be physically delivered to the user of the active pharmaceutical ingredient and / or its intermediate. The active pharmaceutical ingredient and / or its intermediate may be linked to a QR code® on which the active pharmaceutical ingredient and / or its intermediate identifier is encoded. The user of the active pharmaceutical ingredient and / or its intermediate may read the QR code® via a QR code® reader 206. The active pharmaceutical ingredient and / or its intermediate identifier may be provided to a database 208 associated with the consumer or customer of the active pharmaceutical ingredient and / or its intermediate 104. In other embodiments, the consumer / customer of the active pharmaceutical ingredient and / or its intermediate may read the active pharmaceutical ingredient and / or its intermediate identifier via a distributed database 200.

[0090] In this embodiment, the data owner may be an input material producer, an output material producer, an output material user, or an end product producer. The data owner may include any entity that generates data. A data generation node may be connected to a data owner, or an entity that owns or produces the physical product from which data is generated or for which data is generated. The data may be generated by a third-party entity instead of an entity that owns the physical product from which or for which data is generated.

[0091] The data consumption service 210 may include computer executable instructions for accessing and / or processing data such as pharmaceutical active ingredient and / or intermediate data associated with the data owner. The data provision service 210 may include computer executable instructions for providing and / or processing data such as pharmaceutical active ingredient and / or intermediate data associated with the data owner for access and / or processing by the data consumption service 214.

[0092] Based on the received pharmaceutical active ingredient and / or intermediate identifier, a request to access environmental attributes associated with the pharmaceutical active ingredient and / or intermediate identifier may be triggered by the data consumption service 210, as indicated by arrow 212. The pharmaceutical active ingredient and / or intermediate identifier may be provided to the data provision service 214, associated with or from the producer of the pharmaceutical active ingredient and / or intermediate 104. In addition, authentication and / or authorization information may be provided.

[0093] Requests to access environmental attributes associated with pharmaceutical active ingredients and / or their intermediate identifiers may be certified and / or authorized. Based on the success of authorization and / or certification, access to environmental attributes associated with pharmaceutical active ingredients and / or their intermediate identifiers may be permitted.

[0094] For access, the pharmacokinetic active ingredient and / or intermediate identifier may be provided to the data provision service 214, as indicated by arrow 212. The data provision service 214 may use the received pharmacokinetic active ingredient and / or intermediate identifier to read the environmental attributes associated with the pharmacokinetic active ingredient and / or intermediate 104, as indicated by arrows 218 and 220. The environmental attributes associated with the pharmacokinetic active ingredient and / or intermediate 104 provided to the data provision service 214 may be provided to the data consumption service 210, as indicated by arrow 216. The environmental attributes associated with the pharmacokinetic active ingredient and / or intermediate 104 may be stored in the database 208 associated with the user of the pharmacokinetic active ingredient and / or intermediate 104, as indicated by arrow 220.

[0095] Environmental attributes can be uniquely associated with pharmaceutical active ingredients and / or their intermediates via a production identifier or a distributed identifier. Environmental attributes can be transferred between producers and users of pharmaceutical active ingredients and / or their intermediates via a distributed network. In this way, environmental attributes can be shared between value chain players without direct central mediation, accompanied by a unique association with pharmaceutical active ingredients and / or their intermediates. This enables transparency of environmental attributes throughout the value chain, allowing positive environmental impacts from pharmaceutical active ingredients and / or their intermediates produced by the chemical production network 102 to be tracked throughout the value chain.

[0096] Figure 5 schematically illustrates one embodiment of a method or apparatus for providing environmental attributes associated with pharmaceutical active ingredients and / or intermediates across the entire value chain via a distributed network.

[0097] In the embodiment shown in Figure 5, a fully connected value chain including a chemical production network is illustrated. In the embodiment, input material providers, pharmaceutical active ingredient and / or intermediate producers, pharmaceutical active ingredient and / or intermediate users, and final product producers may be connected to a distributed network, as described in relation to Figure 4. Environmental attributes may be provided via an ID-based schema, as described in relation to Figures 2-4, in the form of digital assets associated with the physical entities of input materials, pharmaceutical active ingredient and / or intermediate passports, any intermediate products, or final products, or as pharmaceutical active ingredient and / or intermediate passports.

[0098] Input material providers may provide input materials such as biogas or pyrolysis oil. Environmental attributes of input materials may be provided via data provision services connected to a decentralized network, as illustrated in relation to Figure 4. Pharmaceutical active ingredient and / or intermediate producers may produce pharmaceutical active ingredients and / or intermediates from input materials provided to the chemical production network. Pharmaceutical active ingredient and / or intermediate producers may access environmental attributes associated with input materials via data consumption services connected to a decentralized network, as illustrated in relation to Figure 4. Pharmaceutical active ingredient and / or intermediate producers may manage environmental attributes via a production operating system, as illustrated in relation to Figures 1-3. Pharmaceutical active ingredient and / or intermediate producers may assign environmental attributes associated with input materials, or environmental attributes associated with the chemical production network, such as carbon footprint, to pharmaceutical active ingredients and / or intermediates, as illustrated in relation to Figures 1-3. Producers of active pharmaceutical ingredients and / or their intermediates may provide environmental attributes associated with the active pharmaceutical ingredients and / or their intermediates through data provision services connected to a decentralized network, as illustrated in relation to Figure 4. Users of active pharmaceutical ingredients and / or their intermediates or final product producers may access environmental attributes associated with the active pharmaceutical ingredients and / or their intermediates through data consumption services connected to a decentralized network, as illustrated in relation to Figure 4.

[0099] In this embodiment, the respective data owners could be input material producers, output material producers, output material users, and final product producers. A data owner may include any entity that generates data. A data generation node may be connected to a data owner, or an entity that owns or produces the physical product from which data is generated. Data may be generated by a third-party entity instead of the entity that owns the physical product from which data is generated.

[0100] A data consumption service may include computer executable instructions for accessing and / or processing data, such as pharmaceutical active ingredient and / or intermediate data, associated with the data owner. A data provision service may include computer executable instructions for providing and / or processing data, such as pharmaceutical active ingredient and / or intermediate data, associated with the data owner, for access and / or processing by the data consumption service.

[0101] In the embodiment shown in Figure 5, the distributed identifier may be associated with the final product. Such a distributed identifier may be provided to value chain stakeholders. Through the final product-specific distributed identifier, data associated with the final product produced from the active pharmaceutical ingredient and / or its intermediates may be collected throughout the production chain and assigned to the final product-specific distributed identifier. For example, one or more environmental attributes associated with the final product may be derived from environmental attributes associated with the active pharmaceutical ingredient and / or its intermediates, input materials, or any other product entity present in the value chain of the final product.

[0102] In this way, the environmental attributes of input materials, active pharmaceutical ingredients and / or their intermediates, and any products produced from active pharmaceutical ingredients and / or their intermediates can be tracked throughout the value chain to the final product. Tracking the environmental attributes of materials in this manner makes information transparent throughout the entire value chain, while allowing the flow of information to be controlled by the stakeholders in the supply chain. In addition, environmental attributes can be handled by the production operating system according to the needs of individual stakeholders, as explained in relation to Figures 1 to 3. Overall, such tracking enables individual supply chain stakeholders to track positive environmental impacts, which makes positive environmental impacts transparent and linkable to individual supply chain stakeholders.

[0103] Figure 6 schematically illustrates one example of a chemical production network for producing pharmaceutical active ingredients and / or intermediates associated with digital assets, such as ibuprofen. The example in Figure 6 is illustrative and should not be considered limiting.

[0104] In the embodiment shown in Figure 6, natural gas and / or biomethane may be supplied to a chemical production network for the production of ibuprofen, for example. In this embodiment, natural gas and biomethane may be input materials as mixed feedstocks. Acetic anhydride and other intermediate materials may be produced from natural gas and biomethane. Ibuprofen and other products such as intermediate materials or output materials may be produced from acetic anhydride.

[0105] In the embodiment shown in Figure 6, the biomethane content of the biobased material as an input material can be tracked. As described in relation to Figure 2, the biomethane content at the start of the ibuprofen production chain can be registered via the production operating system 106, where the biomethane content can be allocated to the balance account 112 for the biobased material. Thus, the environmental attributes of the biomethane content are separated from the mass flow of chemical processing in the chemical production network 102, as shown in Figure 6.

[0106] The biomethane content can be determined in order to link it to the biomethane content used in the production of ibuprofen. The biomethane content that can be linked to ibuprofen production can be based on the conservation of mass that can be linked to the produced ibuprofen. For example, only half of the biomethane content may be linked to ibuprofen, and the other half may be linked to other products obtained from biomethane as an input material. The biomethane content of environmental attributes can be linked to ibuprofen to the extent described above.

[0107] In the system shown in Figure 2, environmental attributes associated with the production of the active pharmaceutical ingredient and / or its intermediates can be linked to the produced active pharmaceutical ingredient and / or its intermediates by associating a distributed ID with the active pharmaceutical ingredient and / or its intermediates and assigning the environmental attributes to the distributed ID. By linking the ID and the environmental attributes, the environmental attributes can be uniquely linked to the produced active pharmaceutical ingredient and / or its intermediates. The active pharmaceutical ingredient and / or its intermediates can be delivered to users of the active pharmaceutical ingredient and / or its intermediates. Packaging containing the active pharmaceutical ingredient and / or its intermediates, such as loose bags, may include a QR code®. The distributed ID may be included in or encoded within the QR code®. In this way, users of the active pharmaceutical ingredient and / or its intermediates can access the environmental attributes associated with the active pharmaceutical ingredient and / or its intermediates via the ID-based protocol described in relation to Figures 4 and 5.

[0108] Similar to this embodiment, a chemical production network for producing pharmaceutical active ingredients and / or intermediates associated with digital assets may be based on the carbon footprint shown in Figure 3.

[0109] Preferred embodiments of this disclosure have been described in conjunction with examples. However, those skilled in the art who practice the invention described in the claims can understand and perform other variations by examining the drawings, this disclosure, and the claims.

[0110] Any of the steps presented herein can be performed in any order. The methods disclosed herein are not limited to any particular order of these steps. It is not necessary that different steps be performed in a specific location or on a specific computing node of a distributed system; that is, each step may be performed on a different computing node using different equipment / data processing.

[0111] As used herein, “determine” also includes “initiate or cause to determine,” “generate” also includes “initiate and / or cause to generate,” and “provide” also includes “initiate or cause to determine, generate, select, transmit and / or receive.” “Initiate or cause to perform an action” includes any processing signal that triggers a computing node or device to perform the respective action.

[0112] In the claims and herein, the terms “equipment” and “including” do not exclude other elements or steps, and the indefinite articles “a” and “an” do not exclude plurals. A single element or other unit may perform the function of several entities or items described in the claims. The mere fact that certain means are described in different dependent claims does not imply that a combination of these means cannot be used in a favorable implementation.

[0113] Any disclosures and embodiments described herein relate to the methods, systems, devices, and computer program elements outlined above, and vice versa. Advantageously, any benefits derived from any embodiment and example are equally applicable to all other embodiments and examples, and vice versa.

[0114] All terms and definitions used herein are to be understood in a broad sense and have their general meanings.

Claims

1. A system for producing pharmaceutical active ingredients and / or intermediates associated with digital assets, wherein the system - A chemical production network configured to produce the pharmaceutical active ingredient and / or intermediate thereof, wherein the pharmaceutical active ingredient and / or intermediate thereof is produced from one or more input materials through one or more chemical processes of the chemical production network, and the one or more input materials and / or the one or more chemical processes are associated with environmental attributes, - A production operating device, A system comprising a production operating device configured to generate the digital assets by providing a distributed identifier associated with the produced pharmaceutical active ingredient and / or intermediate thereof, and one or more environmental attributes of the one or more input materials and / or the one or more chemical processes, wherein the distributed identifier is linked to a digital representation of the one or more environmental attributes, the digital representation includes a representation for accessing the one or more environmental attributes or a portion thereof, the one or more environmental attributes are stored in a database associated with the production material producer for access by the production material user, and access to the one or more environmental attributes is controlled by the production material producer via a unique association of the distributed identifier with the production material producer and the one or more environmental attributes.

2. The system according to claim 1, wherein the pharmaceutical active ingredient and / or intermediate associated with the digital asset is selected from azelaic acid, dexpanthenol, poly[(2-oxopyrrolidine-1yl)ethylene]iodine, L-menthol, ibuprofen, ibuprofen sodium dihydrate, racemic ibuprofen licinate, 2-hydroxyacetophenone, and 4-hydroxyacetophenone.

3. The system according to claim 1 or 2, wherein the digital assets of the pharmaceutical active ingredient and / or intermediate thereof include environmental attributes with a balanced material balance related to the input materials.

4. The system according to any one of claims 1 to 3, wherein the one or more environmental attributes associated with the pharmaceutical active ingredient and / or intermediate thereof are provided from at least one balance account configured to store environmental attributes associated with input materials, the balance account relates to a storage structure associated with environmental attribute types, the one or more environmental attributes are assigned to at least one distributed identifier, and the assignment includes the deallocation of the one or more environmental attributes from the balance account associated with each environmental attribute type.

5. The system according to any one of claims 1 to 4, wherein the one or more environmental attributes are associated with at least one characteristic relating to the environmental impact of the one or more input materials and / or the one or more chemical processes.

6. The system according to any one of claims 1 to 5, wherein the production operating device is configured to collect environmental attributes associated with the produced pharmaceutical active ingredient and / or intermediate before, during, and / or after the production of the pharmaceutical active ingredient and / or intermediate by the chemical production network.

7. The system according to any one of claims 1 to 6, wherein the environmental attributes associated with one or more pharmaceutical active ingredients and / or intermediates produced via a chemical process from one or more input materials supplied to the chemical production network include the environmental attributes associated with the input materials, the chemical process, and / or the chemical production network.

8. The system according to any one of claims 1 to 7, wherein the environmental attributes associated with input materials are provided before, during, and / or after the production of the pharmaceutical active ingredient and / or its intermediates by the chemical production network, and the environmental attributes associated with input materials are allocated to at least one balance account before, during, and / or after the production of the pharmaceutical active ingredient and / or its intermediates by the chemical production network.

9. The system according to any one of claims 1 to 8, wherein the environmental attributes associated with the produced pharmaceutical active ingredient and / or intermediates relate to environmental characteristics generated from process data associated with the chemical treatment of the input materials and / or energy data associated with the energy consumption of the chemical treatment, and the environmental attributes associated with the produced pharmaceutical active ingredient and / or intermediates are generated before, during, and / or after the production of the pharmaceutical active ingredient and / or intermediates by the chemical production network.

10. A method for producing a pharmaceutical active ingredient and / or intermediate thereof associated with a digital asset, wherein the method is carried out by a system for producing output materials associated with the digital asset. - Producing the active pharmaceutical ingredient and / or intermediate thereof from one or more input materials through one or more chemical processes of a chemical production network, wherein the one or more input materials and / or the one or more chemical processes are associated with environmental attributes, - By the production operating device of the system for producing the output materials associated with the digital assets, To provide a dispersion identifier associated with the produced pharmaceutical active ingredient and / or intermediate thereof, and one or more environmental attributes associated with the one or more input materials and / or the one or more chemical processes, and Generating a digital asset by linking the distributed identifier with one or more environmental attributes, wherein the distributed identifier is linked to a digital representation of one or more environmental attributes, the digital representation includes a representation for accessing one or more environmental attributes or a portion thereof, the one or more environmental attributes are stored in a database associated with the material producer for access by the material user, and access to the one or more environmental attributes is controlled by the material producer through a unique association of the distributed identifier between the distributed identifier and the material producer and the one or more environmental attributes. - A method comprising providing the pharmaceutical active ingredients and / or intermediates produced by the chemical production network in association with the digital assets.

11. A pharmaceutical active ingredient and / or intermediate associated with a digital asset including a distributed identifier, wherein the distributed identifier is associated with the pharmaceutical active ingredient and / or intermediate and is linked to one or more environmental attributes of one or more input materials and / or one or more chemical processes used to produce the pharmaceutical active ingredient and / or intermediate.

12. The pharmaceutical active ingredient and / or intermediate according to claim 11, wherein the pharmaceutical active ingredient and / or intermediate thereof is selected from azelaic acid, dexpanthenol, poly[(2-oxopyrrolidine-1yl)ethylene]iodine, L-menthol, ibuprofen, ibuprofen sodium dihydrate, racemic ibuprofen licinate, 2-hydroxyacetophenone, and 4-hydroxyacetophenone.

13. A method for generating digital assets associated with pharmaceutical active ingredients and / or intermediates thereof, wherein the pharmaceutical active ingredients and / or intermediates are produced from one or more input materials through one or more chemical processes of a chemical production network, and the one or more input materials and / or the one or more chemical processes are associated with environmental attributes and are carried out by a production operating device. - To provide a distributed identifier associated with the produced pharmaceutical active ingredient and / or intermediate thereof, and one or more environmental attributes of the one or more input materials and / or the one or more chemical processes used to produce the pharmaceutical active ingredient and / or intermediate thereof, and to generate the digital asset by linking the distributed identifier and the environmental attributes, wherein the distributed identifier is linked to a digital representation of one or more of the environmental attributes, the digital representation includes a representation for accessing one or more of the environmental attributes or a portion thereof, the one or more environmental attributes are stored in a database associated with the producer of the product for access by users of the product, and access to the one or more environmental attributes is controlled by the producer of the product through a unique association of the distributed identifier between the distributed identifier and the producer of the product and the one or more environmental attributes. A method comprising providing the digital asset in association with the produced pharmaceutical active ingredient and / or intermediate thereof, wherein the environmental attributes associated with the pharmaceutical active ingredient and / or intermediate thereof are made accessible to users of the pharmaceutical active ingredient and / or intermediate thereof via the digital asset.

14. A digital asset generated according to the method of claim 13.

15. A method of using the digital asset generated according to the method of claim 13 in the production of a product produced from the pharmacokinetic active ingredient and / or intermediate thereof associated with the digital asset, or a method of using the pharmacokinetic active ingredient and / or intermediate thereof associated with the digital asset according to claim 11 or 12 to produce a product from the pharmacokinetic active ingredient and / or intermediate thereof and to derive a digital asset associated with the product from the pharmacokinetic active ingredient and / or intermediate digital asset.

Images